within Pharmacolibrary.Drugs.ATC.B;

model B05AX01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B05AX01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Erythrocytes, or red blood cells, are administered as blood transfusions to treat or prevent anemia resulting from blood loss, surgery, or various medical conditions. They increase the oxygen-carrying capacity of blood. Erythrocyte transfusions are approved and routinely used in clinical medicine.</p><h4>Pharmacokinetics</h4><p>No conventional pharmacokinetic parameters (e.g., volume of distribution, clearance, etc.) are defined for erythrocytes as they are cellular components rather than typical chemical drugs. Their in vivo fate is governed by cell survival, sequestration, and destruction primarily in the spleen and liver. Typical pharmacokinetic modeling is not applicable.</p><h4>References</h4><ol><li><p>Clifton, J, &amp; Leikin, JB (2003). Methylene blue. <i>American journal of therapeutics</i> 10(4) 289–291. DOI:<a href=\"https://doi.org/10.1097/00045391-200307000-00009\">10.1097/00045391-200307000-00009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12845393/\">https://pubmed.ncbi.nlm.nih.gov/12845393</a></p></li><li><p>Evans, AM, &amp; Fornasini, G (2003). Pharmacokinetics of L-carnitine. <i>Clinical pharmacokinetics</i> 42(11) 941–967. DOI:<a href=\"https://doi.org/10.2165/00003088-200342110-00002\">10.2165/00003088-200342110-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12908852/\">https://pubmed.ncbi.nlm.nih.gov/12908852</a></p></li><li><p>Agteresch, HJ, et al., &amp; Wilson, JH (2000). Pharmacokinetics of intravenous ATP in cancer patients. <i>European journal of clinical pharmacology</i> 56(1) 49–55. DOI:<a href=\"https://doi.org/10.1007/s002280050719\">10.1007/s002280050719</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10853877/\">https://pubmed.ncbi.nlm.nih.gov/10853877</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B05AX01;
